# BBI-940

Source: https://onco.cc/drugs/bbi-940/  
OnCo record `bbi-940` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BBI-940 is an oral small-molecule degrader from Boundless Bio that reached phase 1 for ER-positive/HER2-negative breast cancer and luminal androgen receptor triple-negative breast cancer; development has stopped.

## Summary

BBI-940 is an oral small-molecule degrader from Boundless Bio. An oral selective degrader of a previously undrugged kinesin involved in DNA segregation, including segregation of extrachromosomal DNA (ecDNA) during cell division. Its furthest stage is phase 1, for ER-positive/HER2-negative breast cancer and luminal androgen receptor triple-negative breast cancer. ClinicalTrials.gov registers it in one study linked below. June 2026: company said early pharmacokinetic exposure in KOMODO-1 (human oral bioavailability well below preclinical prediction) did not support continued development (10-Q for quarter ended 30 June 2026). Registry trial NCT07408089 TERMINATED for a business decision related to a corporate transaction, not safety. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest; discontinued
- Code: BBI-940
- Modality: Oral small-molecule degrader
- Mechanism: An oral selective degrader of a previously undrugged kinesin involved in DNA segregation, including segregation of extrachromosomal DNA (ecDNA) during cell division.

## Sources

- Boundless Bio: sec.gov: https://www.sec.gov/Archives/edgar/data/0001782303/000119312526339093/bold-20260630.htm
- Boundless Bio: sec.gov: https://www.sec.gov/Archives/edgar/data/0001782303/000119312526339093/bold-20260630.htm
- Boundless Bio: clinicaltrials.gov: https://clinicaltrials.gov/study/NCT07408089
- ClinicalTrials.gov: trials of BBI-940: https://clinicaltrials.gov/search?intr=BBI-940

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- companies: [Boundless Bio](https://onco.cc/companies/boundless-bio/)
- trials: [Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer](https://onco.cc/trials/nct07408089/)

---
JSON: https://onco.cc/api/v1/entities/bbi-940.json